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Abstract
Background: Comparisons of baseline covariates in randomised controlled trials whilst often undertaken is
regarded by many as an exercise in futility. Because of randomisation the null hypothesis is true for baseline
comparisons and therefore any differences will occur by chance. However, this is only the case if allocations are not
known in advance of recruitment. If this occurs then selection bias at randomisation may be present and it is
possible that the statistical testing of covariates may unveil selection bias. In this paper we show that this is
particularly the case for cluster randomised trials when post-randomised recruitment often occurs and can lead to
selection bias.
Main text: We take a recently published cluster randomised trial that has suffered from selection bias due to
differential recruitment and calculate baseline p values. We show that statistically significant imbalances of p < 0.
0001 occurred in 5 of the 10 covariates. In comparison for an individually randomised trial that had no evidence of
selection bias only 1 p value of p < 0.05 out of 20 tests was observed. Had baseline p values for the cluster trial
been presented to journal editors, reviewers and readers then the results of the trial might have been treated with
more caution.
Conclusion: We argue that the blanket ban of baseline testing as advocated by some may reduce the chance of
identifying deficient cluster randomised trials and this opposition should be reconsidered for cluster trials.
Background
Randomisation ensures that the groups formed are
equivalent in all known and unknown variables except
through chance [1]. In reports of randomised controlled
trials (RCTs) we often see, alongside the description of
the characteristics of trial participants, statistical testing
of any imbalance in each characteristic between the
randomised groups to ‘check’ that the randomisation has
not ‘failed’. There is some debate about the validity of
doing this.
Baseline testing of covariates
One view, which is supported by some leading medical
journals (e.g., the BMJ and the Lancet) and many statisti-
cians [2, 3] and specifically advised against in the
CONSORT statement for individually randomised trials
[4], is that baseline testing is illogical, irrelevant and,
possibly, misleading [5]. The argument for not doing
baseline testing is along the following lines: first, assum-
ing robust randomisation we know the null is true: there
is no difference between the randomised groups in any
of the measured variables except by chance. Second,
with multiple statistical tests of 20 or more baseline
variables it is almost inevitable that one or two will
prove to be ‘statistically significant’. Using significant or
non-significant findings of these tests to inform the trial
analysis can produce an inefficient analysis. Consider a
variable that is highly predictive of outcome (e.g., base-
line pain scores). If this variable has a slight (not statisti-
cally significant) or zero imbalance we may decide not
to include it as a covariate in the final statistical model.
Failure to include a powerful predictor, even if it is in
balance, will reduce the power of the analysis and if
there is an imbalance this will mean the post treatment
differences are also biased.
In contrast, one argument for doing baseline testing or
at least allowing it to be presented in journal papers
(e.g., some papers published in the Journal of the Ameri-
can Medical Association or the New England Journal of
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: david.torgerson@york.ac.uk
2Department of Health Sciences, York Trials Unit, University of York, York, UK
Full list of author information is available at the end of the article
Bolzern et al. BMC Medical Research Methodology          (2019) 19:106 
https://doi.org/10.1186/s12874-019-0750-8
Medicine) is to check that the randomisation has not
been subverted [6]. Proponents of this view, whilst
accepting in a properly randomised trial that on average
one out of every 20 baseline tests will be statistically sig-
nificant, argue that if there are several variables favour-
ing one group or another or there is a highly statistically
significant difference in a key variable then this could be
evidence of research misconduct. For example, an RCT
of surgery showed statistically significant differences in
ages between treated groups and on further investigation
it was found that three out of five centres were subvert-
ing treatment allocation [7]. In this paper we revisit this
debate with respect to cluster randomised controlled
trials.
Main
Cluster randomised trials
Cluster randomised trials are when participants are
randomised as intact groups rather than as individ-
uals. The method is commonly used in educational
interventions, where a school or class is the unit of
allocation [1], and evaluation of activities, such as
health promotion, when doctor might be the unit of
allocation, or where there is a risk of the control
group being contaminated by the intervention (that is
the control participants unintentionally receiving the
intervention). Within a cluster trial there are at least
two different data levels: cluster and patient. For clus-
ter level variables (e.g., patient list size) then random-
isation will on average produce equivalent groups and
therefore ‘baseline’ statistical comparisons are subject
to the same criticisms or support as for individually
randomised trials. However, at the patient level, data
can be at increased risk of selection bias compared
with individually randomised trials [8]. Often, recruit-
ment to cluster trials occurs after randomisation of
the clusters. This reveals the future group allocation
to recruiting researchers, clinicians and, sometimes,
potential participants. This is akin to publicising the
future allocations for an individually randomised trial,
something which is now rare but in the past led to
biased recruitment [9]. Consequently, there is a sig-
nificant risk of selective recruitment into cluster trials
that introduces selection bias [8]. Currently, journals
that do not present baseline testing in individually
randomised studies do not present these either for
cluster trials. We think that it may be acceptable to
present baseline statistical tests for cluster trials that
recruit participants after randomisation to assess
whether there is evidence of selection bias. If such
testing were undertaken and this showed a greater
than expected number of variables that were statisti-
cally significant this may then warrant a more
cautious interpretation of the trial’s results.
Baseline p values
The role of p values to assess the equivalence of a trial’s
treatment groups is quite different in cluster trials com-
pared with individually randomised studies. In the latter
p values are linked to the randomisation of the groups
and this drives the argument as to whether or not it is
valid and helpful to calculate and report them. In con-
trast for cluster trials, where recruitment has taken place
after randomisation, p values are no longer entirely
linked to the randomisation process, rather they are
linked to the recruitment method, which may result in
non-random samples being compared. In the following
we will examine two case studies: one a cluster rando-
mised trial and the other an individually randomised
trial. Both of these were identified from a recent review
by Bolzern [10] and colleagues. The aim of these case
studies is to demonstrate the distribution of baseline p
values in a study where there is no evidence of selection
bias in an individually randomised trial as recruitment
has occurred before randomisation compared with a trial
where recruitment has taken place after randomisation,
which is often the case in a cluster RCT.
Case study: cluster randomised trial
The cluster trial by Brinkman et al. [11] evaluated the
role of infant simulators to prevent teenage pregnancies.
In the trial 57 schools from Western Australia were
allocated using simple randomisation, via a table of ran-
dom numbers, into two groups. After randomisation
girls aged 13–15 years were recruited into the trial. Post
randomisation recruitment to the study groups was
uneven with 50% of eligible girls being recruited in the
control schools compared with 58% in the intervention
group. Girls in the intervention group as well as receiv-
ing the standard health curriculum also received the
‘Virtual Infant Parenting’ programme which consisted of
small group teaching with the participants taking a
virtual infant home for the weekend. The aim of the
intervention was to try and reduce unwanted teenage
pregnancies. The results showed that 17% of girls in the
intervention group had a pregnancy event compared
with 11% of the control group (p = 0.00044). The authors
noted that the control group had a higher proportion of
girls from higher socioeconomic groups, were living with
both parents and less likely to have been responsible for
caring for a baby. In the original paper no baseline p
values were presented and we have calculated these and
present them in the table. As the Fig. 1 shows of the 10
p values calculated six are statistically significant with
five of these being highly significant. The trial design
could have easily avoided this problem by simply identi-
fying all of the eligible girls and gaining their consent
before randomisation – this, then, would have avoided
recruitment bias.
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Case study: individually randomised trial
The second case study is an individually randomised
trial by Liu and colleagues [12]. This study was a RCT to
evaluate the role of acupuncture for reducing urine
leakage among women with stress urinary incontinence.
Women were recruited from this trial from 12 hospitals
in China. Block randomisation (size 6) was used to strat-
ify by hospital and 504 women were randomised to
Fig. 1 baseline comparison of an individually randomised trial and a cluster randomised trial
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either ‘true’ or ‘sham’ acupuncture. The trial found a signifi-
cant benefit of true acupuncture on symptoms (p < 0.001).
In the Fig. 1 we have calculated baseline p values and with
over 20 calculations only one (age) was marginally statisti-
cally significant (p = 0.023); thus suggesting selection bias in
this trial was unlikely.
Estimation of baseline p values
In our analysis of p values for the two case studies we
used the aggregate data. The p-values for the study by
Liu et al. were calculated by using the two-sample t-test
for continuous variables and the chi-squared test for
categorical variables. The p-values for the study by
Brinkman et al. were calculated using a similar method
to that used for Liu et al., with an adjustment made for
clustering. For continuous variables clustering was taken
into account by dividing the test statistic by the design
effect, while for categorical variables clustering was
taken into account by dividing the cell numbers by the
design effect, which for the study by Brinkman et al. was
equal to 1.97. The design effect was calculated using the
ICC assumed in the sample size calculation, the number
of clusters randomised and the total number of partici-
pants who consented and participated. As the authors
only had access to the information provided in the
original baseline table, this was considered the best
method available. However, the authors recommend that
statisticians with access to individual participant data
calculate baseline p-values adjusted for clustering by
fitting a mixed effects model for each baseline covariate
in the table, adjusting for the treatment group as a fixed
effect and cluster as a random effect.
Conclusion
Recruitment bias, which is simply a type of post
randomisation selection bias, is a major problem for
significant numbers of cluster randomised trials. It is
important that the reader of a cluster trial can identify
whether such a problem exists. In this paper we are
recommending that, for cluster trials, formally testing
for baseline imbalances of patient level data should be
considered to help identify weak cluster trials. We have
shown in two case studies the distribution of p values
that might occur when there is clear evidence of recruit-
ment bias (Brinkman et al.11) compared with a study
when recruitment bias is unlikely. If baseline p values
had been presented in the Brinkman trial it may have
led to a more nuanced interpretation of the results and
perhaps the findings would not be deemed as credible
by such as the United Kingdom’s Health service: NHS
choices, which concluded that: “This trial had a good
study design” [13].
We are aware of that ‘baseline statistical tests’ are seen
as an anathema, to some, in individually randomised
trials. However, the arguments over baseline testing
using p values for individually randomised trials are
not relevant here. We are not testing whether the
randomisation process ‘worked’. We are trying,
instead, to identify any evidence that suggests that re-
cruitment bias has occurred and the pre-intervention
group averages are not equivalent. One of this paper’s
referees pointed out that covariate imbalances can be
identified by study statisticians using the ‘eyeball’ test
negating the need for the use of p values. For experi-
enced trialists baseline imbalances can be identified
without the use of p values; however, most readers of
trial research are not experienced statisticians or trial
methodologists. We believe placing p values alongside
these differences makes them difficult to ignore and
furthermore, non-technical experts, such as staff at
NHS choices, might not have rated that the trial had
a ‘good study design’.
We believe the use of p values is one tool that can
help identify recruitment bias. Note that in so doing
we are not checking that the randomisation procedure
has ‘worked’: we assume this to be the case. Using p
values in this way is in addition to the quality assess-
ment of the likelihood of this occurring through the
implementation of the cluster design. Indeed, the use
of baseline p values could be easily combined with
other quality assurance measures such as the Time-
line cluster approach, which graphically describes the
recruitment process and draws the reader’s attention
to whether or not recruitment had occurred before or
after randomisation [14].
The problem of selection bias, due to recruitment
bias, in cluster trials has been identified as a major
problem for a number of years [8, 15]. The recom-
mendation to identify and recruit participants before
randomisation, if possible, has not been implemented
in many trials. Indeed, a recent review of 23 cluster
RCTs published between 2015 and 2017 found only
four (17%) recruited participants before randomisation
[10]. Whilst the recommendation of recruitment
before randomisation, if possible, should remain,
perhaps CONSORT guidance for cluster trials should
include the suggestion of baseline testing of patient
level data, as it is currently silent on this issue.
Including baseline p values for cluster trials may
result in better cluster trial designs in the future.
Using statistical significance testing on baseline
patient level variables in cluster randomised trials,
that recruit participants after randomisation, should
be encouraged as this is a relatively easy method to
detect potential selection bias. This should lead to a
more cautious interpretation of cluster trials where
there is a high prevalence of statistically significant p
values among patient level co-variates.
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